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Abstract: Intraocular pressure (IOP) has a tendency to fluctuate throughout the day, reaching its peak
in the early morning in healthy subjects or glaucoma patients. Likewise, histamine tone also fluctuates
over time, being lower at nighttime. Numerous studies have demonstrated a correlation between
short-term IOP fluctuation and glaucoma progression; however, it has not yet been determined
whether histamine plays a role in IOP fluctuations. The aim of this research was to establish the
distribution of the histamine receptor proteins and respective mRNAs in the eye by western blot,
immunohistochemistry and RT-PCR in New Zealand rabbits. Furthermore, we used a transient ocular
hypertension (OHT) model induced by injection of 50 µL of 5% hypertonic saline into the vitreous
and a stable OHT model (100 µL 0.1% carbomer in the anterior chamber) to address the potential
IOP-lowering ability of H3 receptor (H3R) antagonists (ciproxifan, DL76 and GSK189254). IOPs were
performed with a Tono-Pen at baseline and 60, 120 and 240 min post treatment after transient OHT
induction and, every day for 12 days in the stable OHT model. All histamine receptor subtypes were
localized in the rabbit retina and ciliary body/trabecular meshwork. All the treatments lowered IOP
in a dose-dependent fashion between 0.3% and 1%. More specifically, the effects were maximal with
ciproxifan at 60 min post-dose (IOP60 change = −18.84 ± 4.85 mmHg, at 1%), remained stable until
120 min (IOP120 change = −16.38 ± 3.8 mmHg, at 1%) and decayed thereafter to reach baseline values
at 240 min. These effects were highly specific and dependent on histamine release as pre-treatment
with imetit (H3R agonist, 1%) or pyrilamine (H1R antagonist, 1%) largely blocked ciproxifan-mediated
effects. Color Doppler ultrasound examination was performed to evaluate changes in ophtalmic
artery resistivity index (RI) before and after repeated dosing with DL 76, GSK189254, ciproxifan and
timolol. Chronic treatments with H3R antagonists and timolol improved the vascular performance
of ophthalmic arteries and reduced retinal ganglion cell death. Oxidative stress was also reduced
and measured 8-Hydroxy-2′-deoxyguanosine (8OHdG) expression, and by dihidroethydium (DHE)
staining. These results demonstrated that the histamine system participates in IOP regulation and
that H3R antagonists could represent a future promising therapy for glaucoma. Further studies
should be focused on the long-term IOP circadian fluctuations.
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1. Introduction
Glaucoma is a multifactorial, degenerative disorder of the optic nerve. Progressive optic
neuropathy afflicts more than 60 million people worldwide [1] and is mainly caused by glaucoma.
Glaucoma is a group of eye diseases resulting in progressive ocular neuropathy, characterized by loss of
retinal ganglion cells (RGC) and morphological alterations of the optic nerve head. It is mainly caused
by excessively high intraocular pressure (IOP). This increased pressure within the eye, if untreated, can
lead to a reduction of local perfusion, chronic ischemia leading to the reduction of RGC by autophagy,
and apoptosis [2]. When the number of RGC is no longer suitable for neuronal transmission, the
visual field becomes narrower. The first line of treatment consists of topical IOP-lowering medications,
in other words a baroprotective strategy. A significant number of patients require more than one
medication to achieve adequate baroprotection [3]. The target IOP reduction of 25% is not easily reached
and maintained, especially at night. Detection of the progression of glaucoma is very important for
treatment and intraocular pressure fluctuation is an important topic in recent works as a risk factor for
glaucoma progression. Furthermore, long-term IOP circadian fluctuation is associated with a poor
prognosis [4]. The posterior hypothalamus is involved in circadian rhythm regulation and histamine
is one of the neuro-hormones implicated in the arousal system. Histamine tone is reduced at night
and nocturnal IOP is higher than diurnal pressure; IOP is the result of a balance between secretion
and outflow of aqueous humor. This balance is maintained perfectly in healthy subjects [5], with three
variables being of interest: the rate of aqueous humor formation, resistance to outflow, and episcleral
venous pressure. These variables change at night, with aqueous humor production decreasing during
the night in diurnal mammals like rabbits while drainage facility decreases as well and, as a result,
IOP increases [6]. The histamine system is deeply implicated in circadian rhythm and fulfills a major
role in the maintenance of waking [7]. During the day, histamine tone could play a role in maintaining
the IOP in balance. The histamine neurons are located exclusively in the posterior hypothalamus from
which they project to most areas of the central nervous system and also to the retina via retinopetal
axons [8]. Histamine is responsible for ciliary muscle contraction in human eyes and, therefore, for
IOP reduction [9]. Taken together, this evidence supports a potential role of histamine in the regulation
of IOP. Aqueous humor production or outflow rate can possibly be influenced by histamine, which is
the neurotransmitter of the ascending arousal system, and the contributions of retinopetal axons to
vision may be predicted from the known effects of histamine on retinal neurons [8].
This research aims to validate H3 receptor antagonists, both imidazole (ciproxifan) and
non-imidazole compounds (DL76 and GSK189254) in IOP reduction, and establish whether the
histamine system plays a role in baroprotection and, consequently, in retinal neuroprotection by
reducing oxidative stress. The project also investigates the presence and distribution of histamine
receptor subtypes in the retina, ciliary bodies and trabecular meshwork (TM).
2. Results
2.1. Histamine Receptor Protein and mRNA Expression in the Eye of New Zealand White Rabbits
The protein expression of H1, H3 and H4 receptors was found in the retina, optic nerve and TM.
H2 receptor (H2R) was undetectable in the retina, optic nerve and TM (Figure 1A,B). The mRNA
expression of histamine receptors was present in the retina and TM (Figure 1C). The hippocampus was
used as a positive control for H1 and H3 receptors, the stomach for H2R and the spleen for the H4R.
The mRNA of the H2R was found in all the tissues studied, while expression of the protein was not.
Immunofluorescence analysis revealed the presence of histamine H, H3 and H4 receptors in the RGC
(Figure 1D).
Int. J. Mol. Sci. 2019, 20, 981 3 of 15
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 3 of 15 
 
 
Figure 1. (A) Protein expression of histamine receptor subtypes by Western blot analysis; (B) optical 
densitometry of protein expression, n = 5; (C) mRNA expression by RT-PCR of histamine receptor 
subtypes in the trabecular meshwork (TM), retina and hippocampus, n = 5; (D) representative images 
of H3 and H4 receptors (H3R and H4R) in retinal ganglion cells (RGC) at 100× magnification. 
The presence of mRNA and protein expression of histamine H3R led us to investigate the effects 
of different H3R antagonists (GSK189254, ciproxifan and DL 76) on IOP reduction in models of ocular 
hypertension. 
Figure 1. (A) Protein expression of histamine receptor types by Western blot analysis; (B) optical
densitom try of protein expr ssion, n = 5; (C) mR re sion by RT-PCR of histamine receptor
subtypes in the trabecular meshwork (TM), retina and hippocampus, n = 5; (D) representative images
of H3 and H4 receptors (H3R and H4R) in retinal ganglion cells (RGC) at 100×magnification.
The presence of mRNA and protein expression of histamine H3R led us to investigate the effects
of different H3R antagonists (GSK189254, ciproxifan and DL 76) on IOP reduction in models of
ocular hypertension.
2.2. Pharmacological Studies of H3R Antagonists in Transient Ocular Hypertension Model
Selection of the best dose of H3R antagonists was carried out in different experimental sets
using the transient ocular hypertension model. In the ciproxifan experimental set, IOP rose from
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16.8 ± 5.6 mmHg at baseline to 39.63 ± 4.85 mmHg after hypertonic saline injection (Figure 2A).
Reduction of IOP was greatest with ciproxifan (IOP60 change =−18.84± 4.85 mmHg, at 1%): remaining
stable until 120 min (IOP120 change −16.38 ± 3.8 mmHg, at 1%) and decaying thereafter to reach
baseline values at 240 min (Figure 2B). In the DL76 experimental set, IOP rose from 16.5 ± 3.7 mmHg
at baseline to 39.5 ± 5.2 mmHg after hypertonic saline injection (Figure 2C), IOP60 change at 1%
was −17.45 ± 4.48 mmHg and remained stable until 120 min (IOP120 change −18.38 ± 3.04 mmHg,
at 1%); in the GSK189254 experimental set, IOP rose from 14.9 ± 4.2 mmHg at baseline to 40.2 ±
4 mmHg (Figure 2E). The IOP60 change at 1% was −8.61 ± 4.18 mmHg and the IOP120 change
was −9.92 ± 9.02 mmHg. All the compounds reduced IOP dose-dependently and in a statistically
significant manner with a different profile, ciproxifan and DL76 being more effective than GSK189254
(Figure 2B,D,F). After these series of experiments, we compared the three H3R antagonists at 1%
dose with the gold standard treatment timolol at 1% dose. In this experimental group, IOP rose
from 15.7 ± 3.4 mmHg at baseline to 37.7 ± 4.2 mmHg after hypertonic saline injection (Figure 2G);
ciproxifan and DL76 showed an IOP-lowering profile very similar to timolol (timolol IOP60 change =
−16.5 ± 2.6 mmHg and IOP120 change = −15.12 ± 2.85 mmHg in Figure 2H). No adverse side effects
were observed and the drugs did not cause any changes in pupil diameter.
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Figure 2. (A,B) Ciproxifan intraocular pressure (IOP) time course. *** p < 0.001 ciproxifan 1% at 60′ 
and 120′; ** p < 0.01 ciproxifan 0.5% at 120′; * p < 0.05 ciproxifan 0.5% at 60′ versus vehicle; (C,D) DL76 
IOP time course. *** p < 0.001 DL76 1% at 60′ and 120′; ** p < 0.01 DL76 0.5% at 60′; * p < 0.05 DL76 0.5% 
Figure 2. (A,B) Ciproxifan intraocular pressure (IOP) time course. *** p < 0.001 ciproxifan 1% at 60′ and
120′; ** p < 0.01 ciproxifan 0.5% at 120′; * p < 0.05 ciproxifan 0.5% at 60′ versus vehicle; (C,D) DL76 IOP
time course. *** p < 0.001 DL76 1% at 60′ and 120′; ** p < 0.01 DL76 0.5% at 60′; * p < 0.05 DL76 0.5%
at 120′ versus vehicle; (E,F) GSK189245 IOP time course. ** p < 0.01 GSK189254 1% at 120′; * p < 0.05
GSK189254 1% at 60′ versus vehicle; (G,H) effect of H3 antagonists versus timolol. ** p < 0.01 ciproxifan
1% at 60′; * p < 0.05 DL76 and timolol 1% at 60′ and 120′ versus vehicle. All the results are expressed
as mean ± SEM (n = 5). Two-way ANOVA followed by Bonferroni post hoc test. Compounds were
instilled in drops into the lower conjunctival pocket.
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2.3. Evaluation of Specificity of H3R Antagonistic Action
We evaluated the receptor specificity on IOP reduction by counteracting the H3R antagonism
with a pretreatment with 1% imetit, a histamine H3R agonist. IOP rose from 16.2 ± 3.5 mmHg at
baseline to 40.2 ± 5.3 mmHg after hypertonic saline injection (Figure 3A). The IOP-lowering activity
of ciproxifan was suppressed by imetit pre-treatment (Figure 3B). Treatment with 1% pyrilamine, a
H1R antagonist or with 1% amthamine, a H2R agonist, was also performed. In this experimental set,
IOP rose from 18.8 ± 4.2 mmHg at baseline to 40.2 ± 3.5 mmHg (Figure 3C); The pretreatment with
pyrilamine reverted the hypotensive action of ciproxifan (Figure 3D). Amthamine alone had no effect
on IOP.
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2.4. Evaluation of the IOP Profile after Choroidal Mast Cell Granule Depletion by Compound 48/80 Pre-
Treatment 
In this experimental set, IOP rose from 17.7 ± 3.1 mmHg at baseline to 38.8 ± 3.7 mmHg after 
hypertonic saline injection (Figure 4A). IOP-lowering activity of ciproxifan 1% was suppressed in 
animals pretreated with compound 48/80 (C48/80) for two days before the IOP profile experiments 
(Figure 4B). Ex vivo choroid examination revealed an intense and statistically significant mast cell 
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Figure 3. (A,B) Ciproxifan-Imetit intraocular pressure (IOP) time course. *** p < 0.001 ciproxifan 1%
versus vehicle and versus ciproxifan + imetit 1% at 60′ and 120′; (C,D) amthamine and pyrilamine
IOP time course. *** p < 0.001 ciproxifan 1% at 60′ and 120′ versus amthamine and vehicle; ** p < 0.01
ciproxifan versus ciproxifan + pyrilamine. Data are expressed as mean ± SEM (n = 5). Two-way
ANOVA followed by Bonferroni post hoc test. Compounds were instilled in drops into the lower
conjunctival pocket.
2.4. Evaluation of the IOP Profile after Choroidal Mast Cell Granule Depletion by Compound
48/80 Pre-Treatment
In this experimental set, IOP rose from 17.7 ± 3.1 mmHg at baseline to 38.8 ± 3.7 mmHg after
hypertonic saline injection (Figure 4A). IOP-lowering activity of ciproxifan 1% was suppressed in
animals pretreated with compound 48/80 (C48/80) for two days before the IOP profile experiments
(Figure 4B). Ex vivo choroid examination revealed an intense and statistically significant mast cell
degranulation (Figure 4C,D).
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vehicle; ** p < 0.01 ciproxifan 1% at 60′ versus ciproxifan + C48/80, ciproxifan 1% versus vehicle at 120′;
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Two-way ANOVA followed by Bonferroni post hoc test.; (C) Blue Astra staining of mast cells in the
choroid; (D) *** p < 0.001 C48/80 treated eyes versus saline-treated eyes with Welch’s correction t-test.
Compounds were instilled in drops into the lower conjunctival pocket.
2.5. Effects of Histamine H3R Antagonists on IOP, Ocular Vascular Dynamics, Retinal Ganglion Cell
Conservation and Oxidative Stress in Glaucoma Model
To better understand the role of H3 antagonism on modulating IOP, we evaluated both
non-imidazole (GSK189254 and DL76) and imidazole (ciproxifan) compounds in a stable ocular
hypertension model using timolol as a reference drug, with a daily dosing schedule. IOP rose from
13.5 ± 3.8 to 38.3 ± 1 two days after carbomer injection and remained stable for two weeks in
vehicle-treated animals (Figure 5A). Treatment with 1% ciproxifan and DL76 induced a statistically
significant reduction of IOP starting from day 5. The effect was maintained throughout the whole
experimental period (Figure 5B).
To evaluate the vascular performance at the posterior pole of the eye, we measured systolic and
diastolic velocities by means of Doppler ultrasound studies of the ophthalmic arteries. The Pourcelot
resistivity index (RI) significantly increased in glaucomatous animals compared to naïve ones. The
treatments with 1% ciproxifan or 1% DL76 significantly reduced Pourcelot RI. Similar results were
obtained with 1% timolol (Figure 5C).; mean RI values are reported in Figure 5D.
The death of RGC is the main cause of visual impairment in glaucoma. Repeated-dosing treatment
with H3R antagonists, as well as with timolol, significantly prevented the death of neurons in the RGC
layer. Morphological evaluation of retinae of ciproxifan and timolol groups showed a slightly better
conservation of RGC (Figure 5E,F).
Oxidative stress was quantitatively evaluated by determining 8-Hydroxy-2′-deoxyguanosine
(8OHdG), a marker of DNA damage and, morphologically with dihydroethidium (DHE) staining.
Ciproxifan, DL76 and also timolol significantly reduced 8OHdG formation (Figure 5G). DHE staining
demonstrated that the intensity of signal was very strong in the retina of vehicle-treated hypertensive
eyes, showing a higher oxidative damage in the nuclei of cells of retinal layers of the vehicle group
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in comparison with those of the control (naïve). H3R antagonists and timolol-treated eyes presented
retinal images with a less intense fluorescent signal, thus meaning less damage to DNA.
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189254 at day 11, 12 and timolol at day 12 versus vehicle; (C,D) Pourcelot resistivity index. * p < 0.05
basal (naïve animal) versus vehicle; (E) Retinal ganglion cells (RGC) count: *** p < 0.001 Timolol
versus vehicle (glaucomatous animal). *** p < 0.001 ciproxifan and DL76 a 1% versus vehicle. (n = 5);
(F) representativ i a of he t lin/eosin-stained histological secti ns of retinae from different
treated groups. RGC are visible in the up er la ) 8-Hydroxy-2′-deoxyguanosine (8OHdG), levels.
** p < 0.01 ciproxifan a d timolol 1%; * p < 0.05 rsus vehicle; (H) representative images of DHE
stained histological sections of retina. Data are expressed as ean ± SEM (n = 5). T o way (B) and one
way (C, E and G) ANOVA followed by Bonferroni post hoc test. Compounds were instilled in drops
into the lower conjunctival pocket.
3. Discussion
Our results confirm that histamine plays an important role in IOP regulation. Histamine receptors
are expressed in a neuronal and non-neuronal compartment in the eye in diurnal mammals like rabbits.
In diurnal animals during the night, although aqueous humor production decreases, IOP increases
because of reduced aqueous humor drainage from the eye [6] and this happens when the histaminergic
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system, the arousal system, is less active. In patients enrolled in the Advanced Glaucoma Intervention
Study (AGIS), long-term IOP circadian fluctuation, i.e., ocular hypertension at night, was associated
with disease progression [10]. We demonstrated that histamine receptors are expressed in the retina
and TM, both as mRNA and protein levels, with the exception of H2R, which is expressed only as
mRNA. Our results are in agreement with previous publications demonstrating histamine H1R in
ciliary bodies, preferentially on endothelial cells [11], and H3R of ON-bipolar cell dendrites, in cone
pedicles and rod spherules [12].
Topical treatments with H3R antagonists were effective in reducing IOP both in transient and
stable OHT animal models. Treatments with imidazole (ciproxifan) and non-imidazole (DL76 and
GSK189254) compounds were effective in decreasing IOP at 60 and 120 min more than 25% of the
reduction target, in a dose-dependent way. GSK189254 was less effective in reducing IOP in our rabbit
model. To explain it we need to know more about the pKi of this compound in rabbit tissue, as pKi
in the rat brain was similar to those of the other H3 antagonists. GSK189254 is an H3R antagonist
with high affinity for human (pKi = 9.59–9.90) and rat (pKi = 8.51–9.17) H3Rs comparable to those of
ciproxifan and DL76 (Table A1).
The IOP lowering profile of ciproxifan was counteracted by pre-treatment with the H3R agonist
imetit, confirming a H3R mechanism. The effect of pyrilamine in the prevention of the hypotensive
effect of ciproxifan could implicate the involvement of the H1 receptor in the IOP lowering process.
To confirm this hypothesis and to investigate the local source of histamine, we depleted mast cells
(MC) in the choroid tissue of their granule content with compound 48/80 [13] and, as expected, we
did not observe any ciproxifan effect, suggesting a role of MC histamine in the regulation of IOP. It is
important to consider that, in the central nervous system, approximately 50% of histamine belongs
to the non-neuronal pool [14]. The presence of MC in the meninges and the perivascular district of
the brain blood barrier indicates that this cell type is relevant in neurovascular responses [15]. It is
also possible that compound 48/80-mediated massive release of histamine could down-modulate the
H1 receptors involved in regulation of the intraocular pressure, reproducing the effect of H1 blockade
observed with pyrilamine pretreatment. Histamine could interact with the H1 receptor, a G-protein
receptor (Gq), on the cell surface and activates phospholipase C and the phosphatidylinositol signal
pathway, thus increasing intracellular calcium inducing cell contraction (Figure 6). Histamine, via
H1R, stimulates the production of inositol phosphate and mobilization of intracellular Ca2+ in cultured
human ciliary muscle cells, reducing IOP [9,16].
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Many animal glaucoma models have been developed over the decades [17] and we chose the
carbomer one for its simplicity and reproducibility in order to evaluate the onset and pathological
progression of ocular hypertension in a controlled and reproducible manner [18,19]. The demonstration
of histamine H3R subtype in the ciliary body and TM, not only in the retina, is an original result. The
TM is a specialized tissue responsible for draining the majority of aqueous humor (AH) from the
anterior chamber of the eye, thereby controlling IOP. The localization of H3R at this level is therefore
particularly interesting.
Histamine H3Rs are not expressed exclusively in neurons and not only at a presynaptic level [20].
They are expressed on distinct endocrine cell types in the rat fundi mucosa [21], in the apical membrane,
and near collecting duct cells in the rat kidney, and their expression is significantly increased in diabetic
animals, suggesting its involvement in fluid homeostasis [22].
In the chronic treatment schedule in both ciproxifan and DL76 groups, we observed a decrease of
IOP from the third day of topical treatment, which became statistically significant from day 5. This delay
in the effect suggests a mechanism of action that involves a medium-term process in ocular pathology.
The efficacy of the treatments and therefore an achieved baroprotection is confirmed by the observation
that RGC, evaluated in hematoxylin/eosin-stained retinal sections and morphometrically quantified,
were maintained in the eyes of animals that achieved an adequate and stable IOP reduction during
the experimental procedures. Moreover, we also observed an important reduction of oxidative stress
parameters. The presence of oxidative stress markers is one of the constant findings in the progression
from OHT to optic neuropathy [23]. Oxidative stress markers in the retinae were significantly reduced
by baroprotective treatments. This process was helped by H3 antagonist treatments that improved
vascular performance of ophthalmic arteries, reducing the RI, acting on the third variable of interest
in IOP balance. The TM is responsible for approximately 75% of outflow resistance [24], but the
implementation of the vascular performance is important to maintain an adequate perfusion of the
posterior pole of the eye [25]. Vascular impairment in the eye district is important in the pathogenesis
of normotensive glaucoma.
In conclusion, our findings demonstrate that the histamine system participates in IOP regulation.
H3R antagonists significantly reducing ocular hypertension, preventing RGC loss by an improvement
of vascular performance of the central ophthalmic artery, and reducing oxidative stress could represent
a future promising therapy for glaucoma.
4. Materials and Methods
4.1. Animal Models of Glaucoma
The experimental procedures were carried out in New Zealand albino rabbits. All procedures
on animals conformed to the Association for Research in Vision and Ophthalmology Resolution,
in agreement with the Good Laboratory Practice for the use of animals, with the European Union
Regulations (Directive 2010/63/EU), upon authorization of the National Ethics Committee of the
Italian Ministry of Health (number 1179/2015-PR; 16 November 2015). Male albino rabbits (body
weight 2–2.5 kg) were kept in individual cages; food and water were provided ad libitum. The animals
were maintained on a 12–12 h light/dark cycle in a temperature-controlled room (22–23 ◦C). Animals
were identified with a tattoo on the ear, numbered consecutively. All selected animals underwent
ophthalmic and general examinations before the beginning of the study.
A total of 12 rabbits were used for the parallel study of each of the four compounds and for the
vehicle. The probability of reaching a statistically significant difference between treatment and control
groups was set at 80% with a significance level of 0.05 if the mean difference between treatments was
8 mmHg. The software used for this calculation was a free software called G* power 3 [26].
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4.2. Rabbit Models of Ocular Hypertension and Glaucoma
The transient IOP elevation model (OHT model) was obtained by injection of 0.05 mL of sterile
hypertonic saline (5%) into the vitreous bilaterally in locally anesthetized rabbits with one drop of
0.2% oxybuprocaine hydrochloride [27]. In this model, ocular hypertension was reached in 10 min and
then slowly decreases for 4 h. Compounds were instilled into the lower conjunctival pocket. All the
compounds were given prior to saline injection, and IOP was measured at the very beginning of the
experimental session to establish basal IOP and subsequently at 60, 120 and 240 min.
The chronic IOP elevation model (glaucoma model) was obtained by injection of 0.1 mL carbomer
0.25% (Siccafluid, Farmila THEA Pharmaceutical, Milan, Italy) bilaterally into the anterior chamber of
New Zealand albino rabbits pre-anesthetized with zolazepam plus tiletamine (Zoletil 100, 0.05 mg/kg)
plus xylazine (Xilor 2%, 0.05 mL/kg) i.m. [18,19]. In this model, ocular hypertension was reached in
48 h and maintained for at least two weeks. To evaluate the reliability of the model, IOP was measured
three times a day (at 8 a.m., 2 and 8 p.m.) until stabilization for the first 48 h [28], and then measured
each morning before drug instillation. The carbomer model is a two-week-long period of “once a day”
eye drop instillation and tonometry evaluation.
4.3. IOP Measurements
All IOP measurements were performed by applanation tonometry using a tonopen Avia (Reichert
Technologies, Depew, NY, USA). This method has proven to be as reliable as Goldmann applanation
tonometry or GAT, the most accurate way of measuring IOP [29]. GAT is considered the gold standard
for IOP measurement in clinical practice [30]. Tonopen Avia tonometry was used both in the transient
and chronic IOP elevation model. One drop 0.2% oxybuprocaine hydrochloride diluted 1:1 with saline
was instilled in each eye immediately before each set of pressure measurements. The change in IOP
was calculated as the difference between the mean value of IOP in the different treatments towards the
mean IOP in vehicles at the corresponding timepoints.
4.4. Compounds Used in the Experiments
All compounds were purchased by Sigma Aldrich (Milan, Italy) or Tocris Cookson Inc. (Bristol,
UK) with the exception of ciproxifan, provided by Prof. Holger Stark (Heinrich Heine Institute,
Dusseldorf University, Dusseldorf, Germany) and DL76, a novel non-imidazole H3R antagonist
1-[3-(4-tert-butylphenoxy)propyl]piperidine hydrogen oxalate provided by Dr. Dorota Łaz˙ewska
and Prof. Katarzyna Kiec´-Kononowicz (Department of Technology and Biotechnology of Medicinal
Drugs, Jagiellonian University, Kraków, Poland) [31–34]. Histamine ligands are reported with their
relative receptor affinities in Table A1 [35]. Compound 48/80 (C48/80) was instilled in the eye at a
concentration of 15 µg/kg body weight diluted in saline. The Draize eye test was used to establish if
the formulation of each test compound was suitable for ocular administration [36].
4.5. Pharmacological Evaluation of H3R Antagonists on IOP Reduction in Transient OHT Model: Dose/Effect
and Specificity
The experimental design to find the best dose of different H3R antagonists was carried out in
the transient IOP elevation model with the instillation of an eye drop of 30 µL of compounds at three
different concentrations (0.1, 0.5, 1%) in the ocular cul de sac. The pharmacological evaluation of
the H3R antagonism was studied by pre-treating the animals with 30 µL of the H3R agonist imetit at
equimolar concentration with the H3R antagonist. The same procedure was carried out with the H1R
antagonist pyrilamine and the H2R agonist amthamine.
4.6. Pharmacological Evaluation of H3R Antagonists on IOP Reduction and Baroprotection in Glaucoma Model
We tested the effects of ciproxifan, DL 76, GSK189254, and timolol maleate versus vehicle in
reducing IOP measured as previously described. We evaluated the baroprotective effects of the
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different compounds by hemodynamic evaluation using an eco-color-doppler Philips Ultrasound
HD7 XE (Brothel, WA, USA). All animals underwent color Doppler imaging (CDI) investigation at
the beginning of the experimental procedure and at the end of drug treatments. Special attention
was devoted to the evaluation of retinic artery circulation. Blood flow velocities were measured
and the Pourcelot resistivity index (RI) calculated [19]. Pourcelot RI, a significant indicator of ocular
vascular impairment, is the ratio given by the difference between systolic and diastolic velocity over
systolic velocity.
4.7. Sample Collection
Collection of retinae and ciliary bodies was performed in the basal condition and at the end of
experimental glaucoma. Animals were killed with a lethal dose of anesthetics (zolazepam/tiletamine
and penthotal sodium 0.05g/kg). For each treatment group at least three eyes were excised and fixed
with 4% paraformaldehyde in phosphate-buffered saline for histological analysis and the contralateral
ones dissected to collect the retina and ciliary body, quickly frozen in liquid nitrogen and stored at
−80◦C. Samples of stomach, spleen, and hippocampus were also collected to use as positive controls
for H2, H4 and H1/H3R, respectively.
4.8. Western Blot Analysis of Histamine Receptors
Ciliary bodies, retinae, and stomach were homogenized in ice-cold lysis buffer (NaCl 0.9%,
tris-HCl 20 mmol/L pH 7.6, Triton X-100 0.1%, phenylmethylsulfonyl fluoride 1 mmol/L, leupeptin
0.01%) plus a protease inhibitor cocktail (Cell Signaling, Milan, Italy), sonicated, and centrifuged
at 4 ◦C for 10 min at 10,000 g. Total protein levels were quantified using the Pierce™ BCA Protein
Assay Kitc (Thermo Fisher Scientific, Rockford, IL, USA). Tissue samples (30 µg protein per lane) were
subjected to 8% SDS-PAGE, transferred to nitrocellulose membranes and incubated overnight (4 ◦C)
with H1, H2, H3 and H4R antibodies (Santa Cruz Biotechnology, Dallas, TX, USA). Primary antibodies
were diluted 1:1000 in T-PBS (20 mM Tris-HCl buffer, 150 mM NaCl and 0.05% Tween 20) containing
5% BSA. After three rinses with T-PBS, membranes were incubated with secondary antibodies IgG
conjugated with peroxidase, diluted 1:5000 in T-PBS at RT for 1 h. β-actin protein was used as the
internal control for normalization. The immunoreaction was revealed by enhanced chemiluminescence
(Luminata Crescendo Western HRP substrate, Merck Millipore, Darmstadt, Germany) and quantified
by densitometric analysis with the Image J software (version 1.50, National Institutes of Health,
Bethesda, MD, USA)
4.9. Semi-Quantitative RT-PCR of Histamine Receptors
Total RNA was isolated from a tissue according to the manufacturer’s protocol (NucleoSpin
RNA II; Machery-Nagel, Bethlehem, PA, USA). Concentration and purity were assessed by
spectrophotometric analysis (Genequant-Pro, GE Healthcare, Milan, Italy). Oneµg of total RNA
was reverse-transcribed to cDNA with M-MLV Reverse Transcriptase (Omniscript; QIAGEN, Milan,
Italy) using random primers in a 20µL reaction incubated at 25 ◦C for 5 min followed by 60 min at
42 ◦C and 5 min at 70 ◦C. Two hundred ng of cDNA was amplified as follows: 15 min at 95 ◦C, 1 min of
denaturation at 94 ◦C, 30 s of annealing, and 30 s of extension at 72 ◦C for 38 cycles. Primer sequences
are summarized in Table 1. Amplification products were highlighted with ethidium bromide on 1.5%
agarose gel. The intensities of the bands were quantified by densitometric analysis. The used histamine
receptor gene sequences are reported in Table 1.
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Table 1. Histamine receptor gene sequences used.
Name Primer Sequence (5′-3′) TM (◦C) Name Primer Sequence (5′-3′) TM (◦C) ProductLength (bp)
r H1R F a AGCATGGAACGTCCAGTAGT 58.73 r H1R R TTGCCCTCACACATCCTGTC 59.96 109
r H2R F b GGATACCGCGACTACGAACC 60.32 r H2R R ATCGTGGGAAAGCTGACACG 60.67 94
r H3R F c TCACTGGAGAAGCGCATGAA 59.68 r H3R R GAGCCCAAAGATGCTCACGA 60.39 114
r H4R F d GTAGGAAACGCGGTGGTCAT 60.39 r H4R R TGAGCCAAAACAGGCAGACT 59.82 184
a XM_002713049.2 PREDICTED: Oryctolagus cuniculus histamine receptor H1 (hH1R), transcript variant X1, mRNA,
https://www.uniprot.org/uniprot/G1SGD8; b XM_008255497.1 PREDICTED: Oryctolagus cuniculus histamine H2
receptor-like (LOC103348006), mRNA, https://www.uniprot.org/uniprot/P25021; c NM_001082226.1 Oryctolagus
cuniculus histamine receptor H3 (hH3R), mRNA, https://www.uniprot.org/uniprot/Q0Z7Q9; d XM_002713460.2
PREDICTED: Oryctolagus cuniculus histamine receptor H4 (hH4R), mRNA, https://www.uniprot.org/uniprot/
G1TKW6.
4.10. Immunofluorescence of Ciliary Bodies and Retinae
Histological sections, 5 µm thick, were cut from the paraffin-embedded posterior and anterior
eye samples. The sections were deparaffinized and boiled for 10 min in sodium citrate buffer (10 mM,
pH 6.0; Bio-Optica, Milan, Italy) for antigen retrieval. After a pre-incubation in 1.5% bovine serum
albumin (BSA) in PBS, pH 7.4 for 20 min at RT to minimize the non-specific binding, the sections were
incubated overnight at 4 ◦C with primary antibodies directed against H1-4, diluted 1:100 in 5% BSA
PBS-T (Santa Cruz Biotechnology, Dallas, TX, USA), followed by secondary Alexa Fluor 594-conjugated
IgG (1:500; Jackson ImmunoResearch Europe Ltd., Cambridge House, UK).
The sections were mounted in an aqueous medium (Fluoremount, Sigma, Milan, Italy) with
4′,6-diamidino-2-phenylindole (DAPI). Representative images were acquired by an Olympus BX63
microscope coupled to CellSens Dimension Imaging Software version 1.6 (Olympus, Milan, Italy).
4.11. Determination of 8-Hydroxy-2′-deoxyguanosine
Determination of 8-Hydroxy-2′-deoxyguanosine (8OHdG) was performed in order to evaluate
the oxidative stress induced by chronic ocular hypertension. Frozen ciliary bodies and retinae
samples were thawed at room temperature, and cell DNA isolation was performed as previously
described with minor modifications [37]. Briefly, eye samples were homogenized in 1 mL of 10 mM
PBS, pH 7.4, sonicated on ice for 1 min, added with 1 mL of 10 mmol/L Tris-HCl buffer, pH 8,
containing 10 mmol/L EDTA, 10 mmol/L NaCl, and 0.5% SDS, incubated for 1 h at 37 ◦C with
20 µg/mL RNase 1 (Sigma-Aldrich, Saint Louis, MO, USA) and overnight at 37 ◦C under argon in
the presence of 100 µg/mL proteinase K (Sigma-Aldrich, Milan, Italy). The mixture was extracted
with chloroform/isoamyl alcohol (10/2 v/v). DNA was precipitated from the aqueous phase with
0.2 volumes of 10 mmol/L ammonium acetate, solubilized in 200 µL of 20 mmol/L acetate buffer,
pH 5.3, and denatured at 90 ◦C for 3 min. The extract was then supplemented with 10 IU of P1
nuclease (Sigma-Aldrich) in 10 µL and incubated for 1 h at 37 ◦C with 5 IU of alkaline phosphatase
(Sigma-Aldrich) in 0.4 mol/L phosphate buffer, pH 8.8. All of the procedures were performed in
the dark under argon. The mixture was filtered by an Amicon Micropure-EZ filter (Merck-Millipore
Darmstadt, Germany), and 50 µL of each sample was used for 8OHdG determination using an ELISA
kit (JalCA, Shizuoka, Japan), following the instructions provided by the manufacturer. The absorbance
of the chromogenic product was measured at 450 nm. The results were calculated from a standard
curve based on an 8OHdG solution and expressed as ng/ng of DNA.
4.12. Fluorescent Dye Dihydroethidium (DHE) Staining
Histological sections, 5 µm thick, were cut from the paraffin-embedded posterior and anterior
eye samples, deparaffinized and incubated with fluorescent DHE 2µM (Abcam, Camdridge, UK) in a
humidity chamber for 30 min at 37 ◦C. Coverslips were then placed on the slides and kept in the dark.
The sections were mounted in an aqueous medium (Flouremont, Sigma, Milan, Italy). Flourescence
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was detected (absorbance 518 nm, emission 605 nm) using an Olympus BX61 microscope coupled to
CellSens Dimension Imaging Software, version 1.6 (Olympus, Milan, Italy)
4.13. Statistical Analysis
For each assay, data were reported as mean values (± SEM) of individual average measures
of the different animals per group. The significance of differences among the groups was assessed
by one-way ANOVA or two-way ANOVA for multiple comparisons followed by the Bonferroni
post hoc test and unpaired t-test with Welch’s correction. Calculations were made with Prism 5.1
statistical software (GraphPad Software Inc., San Diego, CA, USA). A probability value (p) of <0.05
was considered significant.
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Abbreviations
RGC retinal ganglion cells
OHT ocular hypertension
IOP intraocular pressure
DHE dihydroethidium
TM trabecular meshwork
HR histamine receptor
MC mast cells
8OHdG 8-hydroxy-2′-deoxy-guanosine
DAPI 4′,6′-diamidino-2-phenylindole
RI resistivity index
CDI color doppler imaging
Appendix A
Table A1. Histamine ligands pKi modified [31–35].
Histamine Ligands hH1R pKi hH2R pKi hH3R pKi hH4R pKi
Pyrilamine/mepyramine 8.8 4.63 <5 <5
Amthamine - 6.82 - 5.30
Ciproxifan <5 <5 7.1 5.73
DL76 - - 7.7 * 4.2 *
GSK189245 - - 9.59 -
* Calculated value from Ki data: pKi = 9 – lgKi.
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